Source:http://linkedlifedata.com/resource/pubmed/id/21596855
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2011-7-15
|
pubmed:abstractText |
We have investigated the prognostic significance of isocitrate dehydrogenase 2 (IDH2) mutations in 1473 younger adult acute myeloid leukemia patients treated in 2 United Kingdom Medical Research Council trials. An IDH2 mutation was present in 148 cases (10%), 80% at R140 and 20% at R172. Patient characteristics and outcome differed markedly between the 2 mutations. IDH2(R140) significantly correlated with nucleophosmin mutations (NPM1(MUT)), whereas IDH2(R172) cases generally lacked other molecular mutations. An IDH2(R140) mutation was an independent favorable prognostic factor for relapse (P = .004) and overall survival (P = .008), and there was no significant heterogeneity with regard to NPM1 or FLT3 internal tandem duplication (FLT3/ITD) genotype. Relapse in FLT3/ITD(WT)NPM1(MUT)IDH2(R140) patients was lower than in favorable-risk cytogenetics patients in the same cohort (20% and 38% at 5 years, respectively). The presence of an IDH2(R172) mutation was associated with a significantly worse outcome than IDH2(R140), and relapse in FLT3/ITD(WT)NPM1(WT)IDH2(R172) patients was comparable with adverse-risk cytogenetics patients (76% and 72%, respectively).
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
1528-0020
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:day |
14
|
pubmed:volume |
118
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
409-12
|
pubmed:meshHeading |
pubmed-meshheading:21596855-Adult,
pubmed-meshheading:21596855-Base Sequence,
pubmed-meshheading:21596855-Case-Control Studies,
pubmed-meshheading:21596855-Cohort Studies,
pubmed-meshheading:21596855-DNA Mutational Analysis,
pubmed-meshheading:21596855-Female,
pubmed-meshheading:21596855-Genotype,
pubmed-meshheading:21596855-Humans,
pubmed-meshheading:21596855-Isocitrate Dehydrogenase,
pubmed-meshheading:21596855-Leukemia, Myeloid, Acute,
pubmed-meshheading:21596855-Male,
pubmed-meshheading:21596855-Middle Aged,
pubmed-meshheading:21596855-Mutation,
pubmed-meshheading:21596855-Prognosis,
pubmed-meshheading:21596855-Recurrence,
pubmed-meshheading:21596855-Survival Analysis,
pubmed-meshheading:21596855-Tumor Markers, Biological
|
pubmed:year |
2011
|
pubmed:articleTitle |
The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.
|
pubmed:affiliation |
Department of Haematology, UCL Cancer Institute, London, United Kingdom.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Evaluation Studies
|